PHOTO
The company has intended to launch 3 immunomodulatory drugs, al-Hendawi said.
The medicines production will be started before 2020’s end subject to regulatory approvals with the self-financed budget of EGP 15 million.
The production capacity of the medicines will be determined by the orders the company will receive from the hospitals and will be delivered through 3 weeks.
The company obtained earlier preliminary approval from the Egyptian Drug Authority to register Favipiravir (200 mg) tablet, one of the drugs used in the treatment of coronavirus.
Sabaa is an Egypt-based company engaged in the pharmaceutical sector. The company’s generic product portfolio includes products focused on different therapeutic categories.
Copyright © 2020 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).